Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 7, 2015, Pages 4162-4172

  Leyva Grado, Victor H ^a   Tan, Gene S ^a   Leon, Paul E ^a   Yondola, Mark ^a,b   Palese, Peter ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Avatar Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI INFLUENZA VIRUS MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; AEROSOL; ANTIVIRUS AGENT; HEMAGGLUTININ;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; HISTOPATHOLOGY; IMMUNOTHERAPY; IN VIVO STUDY; INFLUENZA A; INFLUENZA VIRUS A H1N1; LUNG LAVAGE; MOUSE; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; RESPIRATORY SYSTEM; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS REPLICATION; ANIMAL; BAGG ALBINO MOUSE; BIOAVAILABILITY; DRUG EFFECTS; HUMAN; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H5N1); INFLUENZA, HUMAN; INTRANASAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG; PATHOLOGY; TISSUE DISTRIBUTION; VIROLOGY;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, INTRAVENOUS; AEROSOLS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; FEMALE; HEMAGGLUTININS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA, HUMAN; INJECTIONS, INTRAPERITONEAL; LUNG; MICE; MICE, INBRED BALB C; TISSUE DISTRIBUTION;

EID: 84935871962     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00290-15     Document Type: Article

References (25)

1. Renegar KB, Small, PA, Jr. 1991. Passive transfer of local immunity to influenza virus infection by IgA antibody. J Immunol 146:1972-1978.
2. Saylor C, Dadachova E, Casadevall A. 2009. Monoclonal antibody-based therapies for microbial diseases. Vaccine 27(Suppl):G38-G46. http://dx.doi.org/10.1016/j.vaccine.2009.09.105.
3. Luke T, Kilbane EM, Jackson JL, Hoffman SL. 2006. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med 145:599-609. http://dx.doi.org/10.7326/0003-4819-145-8-200610170-00139.
4. Luke T, Casadevall A, Watowich SJ, Hoffman SL, Beigel JH, Burgess TH. 2010. Hark back: passive immunotherapy for influenza and other serious infections. Crit Care Med 38:e66-e73. http://dx.doi.org/10.1097/CCM.0b013e3181d44c1e.
5. Hung IFN, To KKW, Lee CK, Lee KL, Yan WW, Chan K, Chan WM, Ngai CW, Law KI, Chow FL, Liu R, Lai KY, Lau CCY, Liu SH, Chan KH, Lin CK, Yuen KY. 2013. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A (H1N1) infection. Chest 144:464-473. http://dx.doi.org/10.1378/chest.12-2907.
6. Null D, Jr, Pollara B, Dennehy PH, Steichen J, Sánchez PJ, Givner LB, Carlin D, Landry B, Top FH, Jr, Connor E. 2005. Safety and immunogenicity of palivizumab (Synagis) administered for two seasons. Pediatr Infect Dis J 24:1021-1023. http://dx.doi.org/10.1097/01.inf.0000183938.33484.bd.
7. Dunand CJ, Leon PE, Kaur K, Tan GS, Zheng NY, Andrews S, Huang M, Qu X, Huang Y, Salgado-Ferrer M, Ho IY, Taylor W, Hai R, Wrammert J, Ahmed R, Garcia-Sastre A, Palese P, Krammer F, Wilson PC. 2015. Preexisting human antibodies neutralize recently emerged H7N9 influenza strains. J Clin Invest 125:1255-1268. http://dx.doi.org/10.1172/JCI74374.
8. DiLillo DJ, Tan GS, Palese P, Ravetch JV. 2014. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo. Nat Med 20:143-151. http://dx.doi.org/10.1038/nm.3443.
9. Tan GS, Krammer F, Eggink D, Kongchanagul A, Moran TM, Palese P. 2012. A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo. J Virol 86:6179-6188. http://dx.doi.org/10.1128/JVI.00469-12.
10. Heaton NS, Leyva-Grado VH, Tan GS, Eggink D, Hai R, Palese P. 2013. In vivo bioluminescent imaging of influenza A virus infection and characterization of novel cross-protective monoclonal antibodies. J Virol 87: 8272-8281. http://dx.doi.org/10.1128/JVI.00969-13.
11. Krammer F, Hai R, Yondola M, Tan GS, Leyva-Grado VH, Ryder AB, Miller MS, Rose JK, Palese P, Garcia-Sastre A, Albrecht RA. 2014. Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets. J Virol 88:3432-3442. http://dx.doi.org/10.1128/JVI.03004-13.
12. Shao H, Ye J, Vincent AL, Edworthy N, Ferrero A, Qin A, Perez DR. 2011. A novel monoclonal antibody effective against lethal challenge with swine-lineage and 2009 pandemic H1N1 influenza viruses in mice. Virology 417:379-384. http://dx.doi.org/10.1016/j.virol.2011.06.021.
13. Short KR, Veldhuis Kroeze EJB, Fouchier RAM, Kuiken T. 2014. Pathogenesis of influenza-induced acute respiratory distress syndrome. Lancet Infect Dis 14:57-69. http://dx.doi.org/10.1016/S1473-3099(13)70286-X.
14. Ye J, Shao H, Hickman D, Angel M, Xu K, Cai Y, Song H, Fouchier RAM, Qin A, Perez DR. 2010. Intranasal delivery of an IgA monoclonal antibody effective against sublethal H5N1 influenza virus infection in mice. Clin Vaccine Immunol 17:1363-1370. http://dx.doi.org/10.1128/CVI.00002-10.
15. He F, Kumar SR, Khader SMS, Tan Y, Prabakaran M, Kwang J. 2013. Effective intranasal therapeutics and prophylactics with monoclonal antibody against lethal infection of H7N7 influenza virus. Antiviral Res 100:207-214. http://dx.doi.org/10.1016/j.antiviral.2013.08.003.
16. Rinaldi C, Penhale WJ, Stumbles PA, Tay G, Berry CM. 2014. Modulation of innate immune response by influenza-specific ovine polyclonal antibodies used for prophylaxis. PLoS One 9:e89674. http://dx.doi.org/10.1371/journal.pone.0089674.
17. Vieira P, Rajewsky K. 1988. The half-lives of serum immunoglobulins in adult mice. Eur J Immunol 18:313-316. http://dx.doi.org/10.1002/eji.1830180221.
18. Sigounas G, Harindranath N, Donadel G, Notkins AL. 1994. Half-life of polyreactive antibodies. J Clin Immunol 14:134-138. http://dx.doi.org/10.1007/BF01541346.
19. Renegar KB, Small PA, Jr, Boykins LG, Wright PF. 2004. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J Immunol 173:1978-1986. http://dx.doi.org/10.4049/jimmunol.173.3.1978.
20. Maillet A, Guilleminault L, Lemarie E, Lerondel S, Azzopardi N, Montharu J, Congy-Jovilet N, Reverdiau P, Legrain B, Parent C, Douvin DH, Hureaux J, Courty Y, De Monte M, Diot P, Paintaud G, Le Pape A, Watier H, Heunze-Vourch N. 2011. The airways, a novel route for delivering monoclonal antibodies to treat lung tumors. Pharm Res 28:2147-2156. http://dx.doi.org/10.1007/s11095-011-0442-5.
21. Guilleminault L, Azzopardi N, Arnoult C, Sobilo J, Herve V, Montharu J Guillon A, Andres C, Herault O, Le Pape A, Diot P Lemarie E, Paintaud G, Gouilleux-Gruart V, Heunze-Vourch N. 2014. Fate of inhaled monoclonal antibodies after deposition of aerosolized particles in the respiratory system. J Control Release 196:344-354. http://dx.doi.org/10.1016/j.jconrel.2014.10.003.
22. Wagner DK, Clements ML, Reimer CB, Snyder M, Nelson DL, Murphy BR. 1987. Analysis of immunoglobulin G antibody responses after administration of live and inactivated influenza A vaccine indicates that nasal wash immunoglobulin G is a transudate from serum. J Clin Microbiol 25:559-562.
23. Novak M, Moldoveanu Z, Schafer DP, Mestecky J, Compans RW. 1993. Murine model for evaluation of protective immunity to influenza virus. Vaccine 11:55-60. http://dx.doi.org/10.1016/0264-410X(93)90339-Y.
24. Mancini N, Solforosi L, Clementi N, De Marco D, Clementi M, Burioni R. 2011. A potential role for monoclonal antibodies in prophylactic and therapeutic treatment of influenza. Antiviral Res 92:15-26. http://dx.doi.org/10.1016/j.antiviral.2011.07.013.
25. American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee. 2014. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 134:415-420. http://dx.doi.org/10.1542/peds.2014-1665.